ÂÜÀòÂÒÂ×

Ellen Lubman is an accomplished leader in the life sciences sector with extensive experience in business development, strategic advising, and board governance. Currently serving as a Member of the Board of Directors at Cytovation ASA and Reunion Neuroscience Inc., Ellen also holds the position of Chief Business Officer and Head of Investor Relations at Werewolf Therapeutics. With a history of strategic roles at companies like GeneCentric Therapeutics and Impel NeuroPharma, Ellen has demonstrated expertise in navigating the intersection of biotechnology and pharmaceutical innovation. Educational credentials include an MBA in Global Management from Stanford University and a BA in Biological Sciences from Rutgers University, complemented by certification in Pharmacology and Molecular Biology from the University of Medicine and Dentistry of New Jersey.